Elevated antiviral, myeloid and endothelial inflammatory markers in severe COVID-19
Ryan S. Thwaites(University of Oxford), Peter Openshaw(University of Oxford), Yanick J. Crow(St James's University Hospital), Felicity Liew(Imperial College London), Christopher Chiu(Imperial College London), David Hunt(Mott MacDonald (United Kingdom)), Stephanie Ascough(Imperial College London), Annemarie B Docherty(Edinburgh Royal Infirmary), Matthew K. Siggins(Lung Institute), J. Kenneth Baillie(University of Edinburgh), Graham P. Taylor(Imperial College London), Malcolm G. Semple(University of Liverpool), Simon T. Abrams(University of Liverpool), Ashley Sanchez Sevilla Uruchurtu(Lung Institute), Thilipan Thaventhiran(Imperial College London), Ewen M. Harrison(NHS Lothian), Clark D Russell(Centre for Inflammation Research), Shona C. Moore(University of Liverpool), Lance Turtle(University of Liverpool), Charlotte‐Eve Short(Imperial College London), Emma Bergstrom(MRC Centre for Regenerative Medicine), Edwin Carter(Edinburgh Cancer Research), Zoe Gardener(Edinburgh Cancer Research), Tom Solomon(University of Liverpool)
Cited by 9
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
|Nature Immunology|2020|1.4k
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
|Cell|2022|1k
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
|Nature Microbiology|2022|724